Oxandrolone

DHT-derived — no aromatization. High anabolic to androgenic ratio on paper. Does not convert to estrogen or DHT. Modest HPTA suppression relative to other anabolics. 17-AA modification for oral bioavailability. Relatively short half-life of 9-10 hours requires twice-daily dosing for stable levels.

Oxandrolone is orally active via 17-alpha alkylation — no ester is used. The 17-AA modification prevents first-pass hepatic metabolism, allowing oral bioavailability. This modification also causes hepatotoxicity, though oxandrolone is considered less hepatotoxic than stanozolol, oxymetholone, or methyltestosterone.

Oxandrolone is one of the few oral anabolic compounds with a genuinely mild side effect profile relative to what it produces, which is why it has survived in both medical and performance settings. In performance use it is valued for strength increases without significant body weight gain, which makes it particularly useful in weight-class sports and in cutting phases where the goal is maintaining or increasing strength while in a caloric deficit. Female athletes use it more than almost any other anabolic compound because its androgenicity is low enough to produce meaningful results without the virilization that makes most other compounds unusable for women. It also appears in recomposition protocols where someone wants a modest anabolic effect without the estrogenic activity of testosterone.

Oxandrolone is almost always added to an existing protocol rather than forming the core of one. In cutting stacks it pairs with Testosterone Propionate or Testosterone Enanthate as a base, with Masteron often added for the combined effect of strength, hardness, and controlled estrogen. In female protocols it is more often used alone or in very low doses alongside nothing else, specifically because the goal is meaningful effect with minimal androgenic exposure. It is rarely combined with other hepatotoxic orals because the combined liver load is disproportionate to the incremental benefit.

• Weight gain after major surgery, chronic infection, or trauma
• Severe burn injury recovery
• Bone pain associated with osteoporosis
• Turner syndrome in girls
• HIV-associated wasting syndrome
• Constitutional delay of growth and puberty

• Hepatotoxicity — milder than most oral 17-AA steroids
• HPTA suppression — dose-dependent
• HDL suppression — cardiovascular risk
• Androgenic effects — hair loss, acne (mild)
• Virilization in women at higher doses
• Lipid profile alterations
• Peliosis hepatis — rare with oxandrolone but documented

The mildness of Oxandrolone leads to dosing escalation because people assume more is proportionally safer than stronger compounds. It is not. It is a 17-alpha alkylated oral and liver stress is dose-dependent and duration-dependent. The lipid profile impact, particularly HDL suppression, is real and is compounded by longer run durations. HPTA suppression, while milder than most anabolics, is still present and still requires consideration for recovery. Women who exceed reasonable doses or extend use beyond what the compound tolerates risk irreversible virilization effects including voice deepening and clitoral enlargement.

Relatively short detection window of approximately 3 weeks due to shorter half-life and rapid metabolism.